I’m back from another week in San Francisco, where as usual I heard from experts and prognosticators about their expectations for the coming year in biotech.
With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap
